最近の記事

2019/04/10
ゼブラフィッシュ 飼育基本プロトコル
2019/03/04
Dravet 症候群ゼブラフィッシュモデルによる抗てんかん薬in vivoフェノミックスクリーニングシステム
2019/02/19
Clinical Implication of Zebrafish-Based Developmental Toxicology
2019/02/14
Frontiers in Systems Pharmacogy
2019/02/05
Patient-Derived Cancer Xenograft-Driven Zebrafish-Based Drug Discovery and Precision Medicine
2019/01/01
謹賀新年２０１９次世代ゼブラフィッシュ創薬とプレシジョンメディシン
2018/12/03
腫瘍血管新生のプレシジョンメディシン
2018/11/20
第４回ゼブラフィッシュ・メダカ創薬研究会基調講演報告
2018/11/07
phenomic screening by Dravet syndrome zebrafish model
2018/10/24
次世代ゼブラフィッシュ創薬とプレシジョンメディシン

一覧に戻る

2018/11/07
  • CiteULike
  • reddit
  • StumbleUpon
  • linkedin
  • Delicious
  • Mendeley
  • はてなブックマーク
  • Youtube
  • Google+
  • Twitter
  • Facebook

phenomic screening by Dravet syndrome zebrafish model

Epilepsy is a common chronic neurological disease affecting almost 1 million people in Japan and 50 million people worldwide. Despite availability of more than two dozen FDA-approved antiepileptic drugs, one-third of patients fail to receive adequate seizure control. Specifically, pediatric genetic epilepsies are often the most severe, debilitating and pharmaco-resistant forms of epilepsy.
The discovery of epilepsy associated genes suggests varied underlying pathologies and opens the door for development of precision medicine for each genetic epilepsy. Over 80% of patients diagnosed with Dravet syndrome carry a de novo mutation within the voltage-gated sodium channel gene SCN1A and these patients suffer with drug resistant and life-threatening seizures. Here we have developed zebrafish models for Dravet syndrome featuring inactivation of SCN1A with an emphasis on phenomics. we will also report recent drug screening efforts using our models with a focus on assay protocols and predictive pharmacological profiles. As the discovery and development phase rapidly moves from the lab-to-the-clinic for Dravet syndrome, it is hoped that this zebrafish-based drug discovery strategy offers a platform for how to approach any genetic epilepsy.

関連リンク